A new cancer treatment has shown promise in reducing TB growth, particularly in drug-resistant bacteria. The medication, tested in unique cellular models, targets Mycobacterium tuberculosis, the bacteria that causes tuberculosis. It helps initiate natural cell death processes in infected cells. TB kills over 1.6 million people each year, and drug resistance is a growing concern. The researchers are hopeful that host-directed therapies, such as this one, can be a game-changer for infectious diseases. The therapy combines two inhibitors and can control TB growth up to 98%.